Forum ophthalmicum – how to take control over accumulation of diagnostic data from macular OCT with benefit for both doctor and patient? Review article

Article Sidebar

PDF PDF (Język Polski)


Published: Sep 30, 2021
DOI: https://doi.org/10.24292/01.OT.300921.Z
Keywords:
wAMD, optical coherent tomography, anti-VEGF therapy, medical data analysis

Main Article Content

Dorota Maria Kaczmarek
Ośrodek Okulistyki Klinicznej Spektrum
http://orcid.org/0000-0002-0397-1115

Abstract

Wet age-related macular degeneration (wet AMD) is a disease which requires regular diagnostic tests such as macular optical coherent tomography which is extremely important both in diagnosis and disease monitoring. With constant aging of the population, we are dealing with an increasing incidence rate of AMD, which makes it even more important to have a tool allowing for quick and precise analysis of anatomical changes in macular region, particularly in the current complicated epidemiological situation when diagnostic time should be used most efficiently to plan the follow-up treatment. Forum® software allows for the precise analysis of many tests performed in a single patient and combining it with treatment effectiveness assessment which substantially accelerates the diagnostics.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Kaczmarek DM. Forum ophthalmicum – how to take control over accumulation of diagnostic data from macular OCT with benefit for both doctor and patient?. Ophthatherapy [Internet]. 2021Sep.30 [cited 2024Nov.16];8(3):160-5. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1555
Issue
Vol 8 No 3 (2021)
Section
Diagnostics
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Chakravarthy U, Wong TY, Fletcher A et al. ‘Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010; 10: 31. http://doi.org/10.1186/1471-2415-10-31.
2. Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med. 2012; 33(4): 295-317. http://doi.org/10.1016/j.mam.2012.04.005.
3. Jager RD, Mieler WF, Miller JW. Age-Related Macular Degeneration. N Engl J Med. 2008; 358(24): 2606–17. http://doi.org/10.1056/NEJMra0801537.
4. Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ. 2010; 340: c981.
5. Wong WL, Su X, Li X et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-16. http://doi.org/10.1016/S2214-109X(13)70145-1.
6. Spaide RF, Jaffe GJ, Sarraf D et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data. Ophthalmology. 2020; 127(5): 616-36. http://doi.org/10.1016/j.ophtha.2019.11.004.
7. Charakterystyka produktu leczniczego: Bayer Pharma AG, Eylea aflibercept.
8. Charakterystyka produktu leczniczego: Novartis, Lucentis ranibizumab.
9. Androudi S, Dastiridou A, Pharmakakis N et al. Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. Adv Ther. 2016; 33: 715-26. http://doi.org/10.1007/s12325-016-0332-7.
10. Treat-and-Extend Strategy: Is There a Consensus? American Academy of Ophthalmology 2016 (access: 5.02.2019).